Amotiv Limited Market Cap ($576.83 Million)
Market Cap & Net Worth: Amotiv Limited (AOV)
Amotiv Limited market cap. Amotiv Limited (TO:AOV) has a market capitalization of $576.83 Million (CA$797.40 Million) as of November 1, 2026. Listed on the TO stock exchange, this Canada-based company holds position #11137 globally and #331 in its home market, demonstrating a -3.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amotiv Limited's stock price CA$11.27 by its total outstanding shares 101376000 (101.38 Million). Also see how efficiently does Amotiv Limited generate cash for how efficiently the company converts equity into cash flow.
Amotiv Limited Market Cap History (2015–2026)
Amotiv Limited market cap history from 2015 to 2026. Data shows growth from $566.14 Million to $826.47 Million (3.90% CAGR). Check Amotiv Limited stock price for real-time trading data and today's change.
Amotiv Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amotiv Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Amotiv Limited equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.99x
Amotiv Limited's market cap is 0.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $787.61 Million | $5.94 Million | $18.56 Million | 132.59x | 42.44x |
| 2017 | $609.40 Million | $8.63 Million | $17.24 Million | 70.58x | 35.34x |
| 2018 | $563.94 Million | $12.50 Million | $24.08 Million | 45.11x | 23.42x |
| 2019 | $555.87 Million | $47.46 Million | $14.52 Million | 11.71x | 38.29x |
| 2020 | $392.34 Million | $199.52 Million | $31.76 Million | 1.97x | 12.35x |
| 2021 | $388.67 Million | $243.48 Million | $15.68 Million | 1.60x | 24.80x |
| 2022 | $379.87 Million | $293.56 Million | -$29.89 Million | 1.29x | N/A |
| 2023 | $380.60 Million | $328.20 Million | -$16.84 Million | 1.16x | N/A |
| 2024 | $391.60 Million | $371.30 Million | $4.33 Million | 1.05x | 90.40x |
| 2025 | $443.67 Million | $450.09 Million | -$5.37 Million | 0.99x | N/A |
Competitor Companies of AOV by Market Capitalization
Companies near Amotiv Limited in the global market cap rankings as of November 1, 2026. Also see how large is Amotiv Limited's balance sheet for a full breakdown of the balance sheet.
Key companies related to Amotiv Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Amotiv Limited (2015–2026)
Market capitalization of Amotiv Limited from 2015 to today. Between 2015 and today, Amotiv Limited's market cap moved from $566.14 Million to $ 826.47 Million, with a yearly change of 3.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$826.47 Million | +86.28% |
| 2025 | CA$443.67 Million | +13.30% |
| 2024 | CA$391.60 Million | +2.89% |
| 2023 | CA$380.60 Million | +0.19% |
| 2022 | CA$379.87 Million | -2.26% |
| 2021 | CA$388.67 Million | -0.93% |
| 2020 | CA$392.34 Million | -29.42% |
| 2019 | CA$555.87 Million | -1.43% |
| 2018 | CA$563.94 Million | -7.46% |
| 2017 | CA$609.40 Million | -22.63% |
| 2016 | CA$787.61 Million | +39.12% |
| 2015 | CA$566.14 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Amotiv Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $576.83 Million USD |
| MoneyControl | $576.83 Million USD |
| MarketWatch | $576.83 Million USD |
| marketcap.company | $576.83 Million USD |
| Reuters | $576.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more